Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms.
Context.--Pathologists can greatly improve patient care and advance the understanding of disease progression by adeptly employing relevant biomarkers when diagnosing myeloid neoplasms. Although the molecular era has ushered in countless molecular biomarkers in this field, the necessary techniques ca...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 147; no. 4; pp. 403 - 413 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Apr2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=162751643&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 162751643 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: Apr2023 vid: 147 iid: 4 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 162751643 162751643 162751643 10.5858/arpa.2021-0558-RA 162751643 ppf: 403 ppct: 10 formats: fmt: @attributes: type: P tig: atl: Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. aug: au: Verma, Anuj Xu, Mina L. affil: Department of Pathology & Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut sug: subj: Biological Markers Leukemia, Myeloid Pathology Immunohistochemistry Phenotype ab: Context.--Pathologists can greatly improve patient care and advance the understanding of disease progression by adeptly employing relevant biomarkers when diagnosing myeloid neoplasms. Although the molecular era has ushered in countless molecular biomarkers in this field, the necessary techniques can be expensive and time-consuming. Novel immunohistochemical biomarkers can help to quickly and inexpensively render the correct diagnosis and predict response to targeted therapies. Hence, it is critical to continue studying and using new and promising immunohistochemical tools for myeloid neoplasms in our current era. Objective.--To review the emerging biomarkers in myeloid neoplasms that can be identified by immunohistochemistry and to discuss their utility, staining patterns, and pitfalls. Data Sources.--We conducted a scientific literature search of articles related to either a novel immunohistochemical marker or a new utility of an already known marker to assess myeloid neoplasms in PubMed from 2016 to September 30, 2021. We curated relevant contributing studies from the references and subsequent citations of the original articles. Conclusions.--Immunohistochemistry is a powerful tool in analyzing biomarkers that play a significant role in the management of patients with myeloid neoplasms. We reviewed 5 immunohistochemical markers, namely, IDH1R132H, ERG, IRF8, GATA1, and NPM1. These markers, depending on the clinical scenario, can be diagnostic, predictive, and also prognostic. Immunohistochemistry also empowers us to evaluate these markers in archival samples, including pretreatment and posttreatment biopsies. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|